Amgen cholesterol drug cuts heart attack, stroke risk more than 20 percent: study

WASHINGTON (Reuters) - Amgen Inc's Repatha drug cut the risk of heart attacks and strokes by over 20 percent in patients with heart disease, demonstrating a clear clinical benefit beyond its ability to slash "bad" LDL cholesterol levels, data from a huge study known as Fourier showed on Friday.